-
Cell Stem Cell Back-to-Back | Ten Years of Grinding a Sword: Development of hPSCs-derived dopamine neuron optimization program and preclinical efficacy evaluation
Time of Update: 2021-05-08
In PD models of mice, rats, and monkeys, the robust implantation of in vitro hPSC-derived mDA neurons requires the development of a floor-derived midbrain dopamine neuron differentiation protocol, and all of these protocols are based on WNT signal activators (usually GSK3).
-
Alzheimer Dementia: Extrapyramidal symptoms can effectively predict the risk of dementia
Time of Update: 2021-05-08
The results of previous studies have shown that the presence of EPS at baseline and the presence of time-varying EPS (capturing the incidence of EPS during follow-up) predicts shorter time to death, cognitive, functional and dependent endpoints, and cognitive The rate of decline is greater.
-
IEEE trans: Functional EEG network to identify refractory epilepsy without structural abnormalities
Time of Update: 2021-05-07
Method for extracting SPN characteristics of RE-no-SA and MCE patients from EEG brain segments in resting stateFirst, a functional and effective network of different frequency bands is constructed from the EEG signal.
-
Neurology: For mild strokes, the combined treatment of thrombolysis and thrombus removal is more effective
Time of Update: 2021-05-07
abstract" target="_blank" rel="noopener">Outcomes, and Neuroimaging of Direct Clinical Thrombectomy VS Bridging, Large Vessel Occlusion Therapy in: the Analysis of the SELECT The Cohort Study neurology.
abstract" target="_blank" rel="noopener">Outcomes, and Neuroimaging of Direct Clinical Thrombectomy VS Bridging, Large Vessel Occlusion Therapy in: the Analysis of the SELECT The Cohort Study neurology.
-
Neurology: Patients with amyloid vascular disease, memory deterioration may reflect tau pathology
Time of Update: 2021-05-07
Statistical analysis was performed to examine the differences in cognitive ability, structural markers of cerebral small vessel disease, and retention of amyloid and tau-PET between CAA participants with and without amnesia.
-
Neurology: In patients with frontotemporal dementia, white matter hyperintensity lesions are closely related to neurodegeneration
Time of Update: 2021-05-07
WMH volume is associated with the risk of cognitive impairment and dementia, including Alzheimer's disease (AD).
The relationship between the volume and distribution of WMH in the whole brain and brain atrophy, disease severity, vascular risk and cognitive ability was explored.
-
The State Food and Drug Administration Revises Rats for Injection
Time of Update: 2021-05-03
Among them, [Note] stressed that the increase "should be strictly in accordance with the instructions provided for the use of dose administration is strictly prohibited to change the route of administration.
-
The safety issue of Pfizer/Lilly's new painkiller tanezumab triggers FD...
Time of Update: 2021-05-03
The US FDA added, “Although the two companies have proposed clinical risk mitigation strategies in the study, the risk of RPOA is still worrying, because a considerable number of patients with adverse events require total joint replacement.
-
Eli Lilly’s business model adjustment for multinational pharmaceutical companies has a large number of drugs "patent cliff" here?
Time of Update: 2021-05-03
With the cancellation of the CCO mixed-line sales team, Eli Lilly said that the business transformation will not affect patients and the company will continue to ensure the commercial supply of these products.
-
The latest research scientist reveals the 3D of the special complex responsible for gene expression in cells...
Time of Update: 2021-05-03
Recently, in a research report titled "Structure of the human Mediator-bound transcription pre-initiation complex" published in the international journal Science, scientists from Northwestern University and other institutions have observed responsibility in human cells for the first time through research.
-
One step closer to listing! Innovative T cell immunotherapy releases clinical data analysis
Time of Update: 2021-05-03
- Recently, T cell immunotherapy company Atara Biotherapeutics, at the 47th European Society for Blood and Marrow Transplantation (EBMT 2021) 2021 Nian March 14 to 17 held online conference to announce the tab-cel for its leading product Comprehensive analysis of 3 phase 2 studies of Epstein-Barr virus (EBV)-related lymphoproliferative disease (EBV+ PTLD) after hematopoietic cell transplantation (HCT) (tabelecleucel, ATA129) , and provides the latest long-term overall survival (OS) Data .
-
Interpretation of Nature Sub-Journal: Scientists have discovered that humans suffer from multiple diseases or have common...
Time of Update: 2021-05-03
Recently, in a research report titled "Plasma metabolites to profile pathways in noncommunicable disease multimorbidity" published in the international journal Nature Medicine, scientists from the University of Cambridge and other institutions have identified through research that it can increase individual suffering from one or more diseases.
-
Pfizer and Moderna refused to cooperate with Johnson & Johnson on the coagulation issue of the new crown vaccine...
Time of Update: 2021-05-02
According to a recent report by the Wall Street Journal, Johnson & Johnson contacted Pfizer, Moderna and AstraZeneca to ask them to investigate the coagulation problem caused by the COVID-19 vaccine and "express opinions on safety issues.
-
Rongchang Biological "Tetaxipu" is officially on sale!
Time of Update: 2021-05-02
In January 2020, Taltazep obtained the US FDA's Phase III clinical trial approval for the treatment of systemic lupus erythematosus in the United States, and obtained fast track qualification in April.
-
CSA&TISC2021 kick-off meeting held in Beijing
Time of Update: 2021-05-02
With the advancement of new technology and clinical transformation, acute stroke reperfusion therapy has become a hot spot in global research in recent years.
-
Izcargo, a biological product that crosses the blood-brain barrier, was approved for the first time on the market
Time of Update: 2021-05-02
A few days ago, JCR Pharmaceuticals announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan has approved Izcargo (pabinafusp alfa) for the treatment of mucopolysaccharidosis type II (MPS II, also known as Hunter syndrome).
Retrieved April 13, 2021, from /JCR-Pharmaceuticals-Announces-Approval-of-IZCARGO%C2%AE-Pabinafusp-Alfa-for-Treatment-of-MPS-II-Hunter-Syndrome-in-Japan
-
Idiopathic narcolepsy drug Xywav oral solution receives priority review by the U.S. FDA
Time of Update: 2021-05-02
In July 2020, Xywav was approved by the US FDA for the treatment of cataplexy or excessive daytime sleepiness (EDS) in narcolepsy (narcolepsy) patients 7 years and older.
-
Rescue the "trapped" mind and body, the survey on the quality of life of Chinese Parkinson's disease patients is launched
Time of Update: 2021-05-02
On April 17, the 4th Parkinson's Disease National Summit Forum hosted by Lingbei China was held in Hangzhou. Authoritative experts in the field of Parkinson's disease diagnosis and treatment in Chin
-
National Health Commission announces new instructions for new crown vaccination
Time of Update: 2021-05-02
Wu Liangyou, deputy director of the National Health Commission's Disease Control Bureau, said that at present, the new crown virus vaccination work is progressing smoothly, and good work experience has also been accumulated in various places.
-
Qilu Pharmaceutical has introduced a "first-in-class" antibody pair...
Time of Update: 2021-05-02
On April 16, Qilu Pharmaceutical and Peptron jointly announced that the two parties have reached an exclusive license agreement for the latter's antibody-conjugated drug (ADC) targeting MUC1.
